ContactISSN:e-ISSN: 2757-976X
Author Sign-inReviewer Sign-inRegister
TürkçeEnglish
Home
About Journal
Copyright NoticeOpen Access PolicyAim and ScopePrinciples of ArbitrationReviewer and Editor GuideFee PolicyEthical Principles and Publication PolicyArchiving PolicyIndexing
Information For AuthorsEditorial BoardSend ArticleLatest IssueArchiveContact Us

Wilson Disease in Children: A Single-Center Experience

Anna Carina Ergani,MELTEM GÜMÜŞ,Vesile Betül Aydın,İlhan Abidin,Mehmet Akif AĞIR,HALDUN EMİROĞLU

  • Anna Carina Ergani: Konya Şehir Hastanesi Çocuk Gastroenterolojisi
  • MELTEM GÜMÜŞ: SELÇUK TIP FAKÜLTESİ
  • Vesile Betül Aydın: SELÇUK TIP FAKÜLTESİ
  • İlhan Abidin: SELÇUK TIP FAKÜLTESİ
  • Mehmet Akif AĞIR: Konya Şehir Hastanesi Çocuk Gastroenterolojisi
  • HALDUN EMİROĞLU: SELÇUK ÜNİVERSİTESİ
  •  Year : 2026
  •  Vol : 6
  •  Issue : 1
  •  Page : 1-7
Objective: This study aims to present the demographic characteristics, clinical findings, laboratory and histopathological data, and treatments administered to pediatric patients diagnosed with Wilson’s disease in our clinic over the past 11 years. Methods: Nineteen pediatric patients diagnosed with Wilson disease between September 1, 2012 and January 1, 2023 at Selçuk University Faculty of Medicine, Department of Pediatric Gastroenterology, were retrospectively analyzed. Clinical, biochemical, radiological and histopathological findings were recorded, and the Ferenci scoring system was used in the diagnostic assessment. Results: Of the patients, 57.8% were male and the mean age at diagnosis was 8.84 ± 3.64 years. The most common reason for admission was incidentally detected elevated transaminases, and 78.9% of patients presented with the hepatic form. Hepatomegaly was the most frequent physical examination finding (52.6%). Kayser–Fleischer rings were present in 31.5% and neurological symptoms in 15.7% of cases. Mean serum ceruloplasmin level was 8.47±8.06 mg/dL, 24-hour urinary copper excretion was 468.42 ± 562.87 µg, and mean hepatic copper concentration (n=16) was 797.63 ± 527.08 µg/g. Genetic confirmation was performed in 10 patients; treatment modification was required in three due to D-penicillamine–related hematological side effects, and one patient underwent liver transplantation. Conclusion: Pediatric Wilson disease shows wide clinical variability but predominantly presents with hepatic involvement. Low ceruloplasmin levels, increased urinary copper excretion and hepatic copper accumulation are key diagnostic indicators, while the Ferenci score enhances diagnostic reliability. Early diagnosis, regular follow-up and treatment adherence positively influence disease progression.
Conflict of interest : The authors declare that they have no conflict of interest.

This article is published under the CC BY-NC 4.0 license.
Mevlana Tıp Bilimleri
2026, Vol6, Issue1
E-ISSN: 2757-976X
Received : , Accepted : , Published Online :

References

  1. 1. Sokol R, O’connor J. Copper metabolism and copper storage disorders. Liver disease in children Cambridge University Press, Cambridge. 2014:465-92.
  2. 2. Reilly M, Daly L, Hutchinson M. An epidemiological study of Wilson's disease in the Republic of Ireland. Journal of Neurology, Neurosurgery & Psychiatry. 1993;56(3):298-300.
  3. 3. Loudianos G, Lovicu M, Solinas P, Kanavakis E, Tzetis M, Manolaki N, et al. Delineation of the spectrum of Wilson disease mutations in the Greek population and the identification of six novel mutations. Genetic testing. 2000;4(4):399-402.
  4. 4. Panagiotakaki E, Tzetis M, Manolaki N, Loudianos G, Papatheodorou A, Manesis E, et al. Genotype–phenotype correlations for a wide spectrum of mutations in the Wilson disease gene (ATP7B). American Journal of Medical Genetics Part A. 2004;131(2):168-73.
  5. 5. Liver EAfSo E. Clinical Practice Guidelines: Wilson's disease. J Hepatol. 2012;56(3):671-85.
  6. 6. Riordan SM, Williams R. The Wilson's disease gene and phenotypic diversity. Journal of hepatology. 2001;34(1):165-71.
  7. 7. Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut. 2007;56(1):115-20.
  8. 8. Socha P, Janczyk W, Dhawan A, Baumann U, D'Antiga L, Tanner S, et al. Wilson's disease in children: a position paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Journal of pediatric gastroenterology and nutrition. 2018;66(2):334-44.
  9. 9. Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. The Lancet Neurology. 2015;14(1):103-13.
  10. 10. Dhawan A. Evaluation of the scoring system for the diagnosis of Wilson's disease in children. Liver International. 2005;25(3):680-1.
  11. 11. Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. Human genetics. 2006;120(2):151-9.
  12. 12. Seo JK. Diagnosis of Wilson disease in young children: molecular genetic testing and a paradigm shift from the laboratory diagnosis. Pediatric Gastroenterology, Hepatology & Nutrition. 2012;15(4):197-209.
  13. 13. Aaraj S, Khan SA, Ali N, Malik MII, Dar FS. Wilson disease in children; chelation therapy or liver transplantation? A 10-year experience from Pakistan. Annals of Transplantation. 2021;26:e932606-1.
  14. 14. Yener S, Akarsu M, Karacanci C, Sengul B, Topalak O, Biberoglu K, et al. Wilson's disease with coexisting autoimmune hepatitis. Journal of gastroenterology and hepatology. 2004;19(1):114-6.
  15. 15. Grandis DJ, Nah G, Whitman IR, Vittinghoff E, Dewland TA, Olgin JE, et al. Wilson's disease and cardiac myopathy. The American journal of cardiology. 2017;120(11):2056-60.
  16. 16. Favre E, Lion‐François L, Canton M, Vanlemmens C, Bonneton M, Bouillet L, et al. Cognitive abilities of children with neurological and liver forms of Wilson disease. Journal of Pediatric Gastroenterology and Nutrition. 2017;64(3):436-9.
  17. 17. Mak CM, Lam C-W, Tam S. Diagnostic accuracy of serum ceruloplasmin in Wilson disease: determination of sensitivity and specificity by ROC curve analysis among ATP7B-genotyped subjects. Clinical chemistry. 2008;54(8):1356-62.
  18. 18. Schilsky ML, Ala A. Wilson disease. Schiff's Diseases of the Liver. 2017:799-819.
  19. 19. Yang X, Tang Xp, Zhang Yh, Luo Kz, Jiang Yf, Luo Hy, et al. Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample. Hepatology. 2015;62(6):1731-41.
  20. 20. Cauza E, Maier-Dobersberger T, Ferenci P. Plasma ceruloplasmin as screening test for Wilson’s disease. J Hepatol. 1997;27:358-62.
  21. 21. Ferenci P, Caca K, Loudianos G, Mieli‐Vergani G, Tanner S, Sternlieb I, et al. Diagnosis and phenotypic classification of Wilson disease 1. Liver International. 2003;23(3):139-42.
  22. 22. Masełbas W, Chabik G, Członkowska A. Persistence with treatment in patients with Wilson disease. Neurologia i neurochirurgia polska. 2010;44(3):260-3.
  23. 23. Taylor RM, Chen Y, Dhawan A, Consortium E. Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King’s College Hospital and review of the literature. European journal of pediatrics. 2009;168(9):1061-8.
  24. 24. Mizuochi T, Kimura A, Shimizu N, Nishiura H, Matsushita M, Yoshino M. Zinc monotherapy from time of diagnosis for young pediatric patients with presymptomatic Wilson disease. Journal of pediatric gastroenterology and nutrition. 2011;53(4):365-7.
  25. 25. Arnon R, Annunziato R, Schilsky M, Miloh T, Willis A, Sturdevant M, et al. Liver transplantation for children with Wilson disease: comparison of outcomes between children and adults. Clinical transplantation. 2011;25(1):E52-E60.